Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

M0 acute non lymphocytic leukemia (M0-ANLL)

Identity

Note Stasi's criteria
  • 30% blast cells in the bone marrow with <50% erythroblasts
  • Cytochemical staining MPO/SSB <3% of blasts
  • Cytochemical staining for PAS, AcP and NSE negative or weak
  • At least one of these three immunologic markers positive : MPO, CD13, CD33, in flow cytometry or ultrastructurally
  • Absence of cCD3, cCD22 and cCD79a
    		•
    Other namesMinimally differentiated acute leukemia

    Clinics and Pathology

    Epidemiology rare: 3 - 5 % of ANLL; med age 45 yrs; 20% are children; unbalanced sex ratio in the adults: 1.6 M/1F, p< 0.01
    Clinics High WBC mostly in children; frequently low Hb and platelets; organomegaly in children
    Cytology Undifferentiated blasts, cytochemistry: negative for myeloperoxydase. Positivity of at least one myeloid marker (CD13, CD33, CD65, CD117-c-KIT). Frequent expression of early progenitor markers CD34, DR; TdT in 30-40% of the cases; CD7 expression frequent in children. MPO antigen identified in about 50% of the cases.
    Prognosis Poor: CR in 50% of cases, med survival: 8 mths Poor prognosis factors: older age, high WBC, low platelets, CD10, CD14, CD15.

    Cytogenetics

    Cytogenetics Morphological high percentage of complex (20%) and unbalanced karyotypes; partial or complete monosomy (5/del(5q, -7/del(7q), or rearrangements of chromosome 5 and/or 7 in 15-20%; chromosome 11 rearrangements (11q23 in particular), and chromosome 8 involvement (+8) in 10-15%; chromosome 13 involvement ( +13) in 9% ;t(9;22)(q34;q11) in 5%; near-tetraploidy in 6%; normal karyotype in 25%

    Bibliography

    The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
    Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA, Olive D
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999 ; 13 (10) : 1513-1518.
    PMID 10516751
     
    AML-M0: a review of laboratory features and proposal of new diagnostic criteria.
    Stasi R, Amadori S
    Blood cells, molecules & diseases. 1999 ; 25 (2) : 120-129.
    PMID 10389594
     
    Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.
    Bˆ©nˆ© MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matutes E, Orfao A, Schoch C, Sperling C, van't Veer MB
    British journal of haematology. 2001 ; 113 (3) : 737-745.
    PMID 11380465
     

    Contributor(s)

    Written12-1999Jean-Loup Huret
    Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

    Citation

    This paper should be referenced as such :
    Huret JL . M0 acute non lymphocytic leukemia (M0-ANLL). Atlas Genet Cytogenet Oncol Haematol. December 1999 .
    URL : http://AtlasGeneticsOncology.org/Anomalies/M0ANLLID1057.html
    Bene MC . M0 acute non lymphocytic leukemia (M0-ANLL). Atlas Genet Cytogenet Oncol Haematol. .
    URL : http://AtlasGeneticsOncology.org/Anomalies/M0ANLLID1057.html

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Mon May 12 18:11:19 2008

    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    j.l.huret@chu-poitiers.fr.